Image

STAR and Deferred Stenting Study

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

STAR is a minimal-risk pragmatic clinical trial of patients admitted for a CTO-PCI procedure. The overall objective of the STAR Study is to address the current gaps in knowledge regarding use of STAR during CTO-PCI, as a prospective, multi-center study of 150 participants with randomization of timing of staged PCI. Five sites will be selected to participate in STAR from a national network of highly experienced CTO-PCI centers across the United States.

Description

To date, there have been no studies that prospectively and systemically evaluated the efficacy and safety of STAR with deferred stenting and described the frequency of its use in the hybrid approach. The aim of this study is to address these current gaps in knowledge, including the frequency of use of STAR by experienced operators, the safety of its use, optimal timing of staged stenting and health status change associated with this procedure. This prospective study will enroll 150 patients undergoing elective PCI of native CTO utilizing the STAR technique and will subsequently randomize patients in a 1:1 fashion to early (5-7 weeks) and later (12-14 weeks) timing of subsequent stenting.

Eligibility

Inclusion Criteria:

  1. Subject is scheduled for a PCI procedure for at least one chronic total occlusion with TIMI antegrade flow of zero.
  2. Subject is ≥ 18 years of age at the time of consent
  3. The operator attempted STAR technique defined as knuckle guidewire across or into the CTO segment during the CTO PCI and is planned for a staged procedure.
  4. English speaking due to follow up.

Exclusion Criteria:

  1. The CTO segment is in a graft.
  2. Female subjects with a positive quantitative or qualitative pregnancy test, in accordance with hospital policy.
  3. Unable to participate in telephone follow-up
    1. Too hard of hearing to do follow-up by telephone or deaf.
    2. Incarcerated prisoner.
    3. History of dementia.
    4. Subjects without a way for contact by telephone for follow-up.
  4. Previously enrolled in STAR.
  5. Patient not a candidate for baseline and final angiography (CKD with eGFR<30).
  6. The knuckled guidewire did not cross into the CTO segment during STAR attempt.
  7. A stent was placed into the STAR segment during the Index Procedure.
  8. Refused participation in the study.
  9. Patient enrolled in another study.

Study details

Coronary Occlusion, Coronary Stenosis, Coronary Restenosis

NCT05089864

Saint Luke's Health System

1 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.